HALOZYME THERAPEUTICS, INC. (HALO)
About HALOZYME THERAPEUTICS, INC.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $1.4B
- Net income
- $316.9M
- Total assets
- $2.5B
- Market cap
- $8.5B
- Gross margin
- 83.6%
- Operating margin
- 33.6%
- Net margin
- 22.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.4B
- Cost of revenue
- $228.8M
- Gross profit
- $1.2B
- Operating expenses
- $698.8M
- Operating income
- $469.0M
- Income tax
- $150.0M
- Net income
- $316.9M
- EPS (basic)
- $2.64
- EPS (diluted)
- $2.56
Balance sheet
- Total assets
- $2.5B
- Current assets
- $825.2M
- Total liabilities
- $2.5B
- Current liabilities
- $177.1M
- Shareholders’ equity
- $48.8M
Cash flow
- Operating cash flow
- $651.6M
- Investing cash flow
- -$545.8M
- Financing cash flow
- -$85.2M
- Net cash flow
- $20.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $8.5B
- P/E ratio
- 32.0
- EPS (diluted)
- $2.56
- Shares outstanding
- 103.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 12, 2004
Halozyme Therapeutics, Inc. (HALO) Stock Price
- Profitable — net income of $316.9M in FY2025.
- Revenue grew 215% from FY2021 to FY2025.
- Gross margin of 83.6%, net margin 22.7%.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 32.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review HALOZYME THERAPEUTICS, INC..
Write a review
News about HALOZYME THERAPEUTICS, INC.
News & sentiment via Polygon.io
Halozyme Therapeutics, Inc.: frequently asked questions
Is Halozyme Therapeutics, Inc. an American company?
Yes — Halozyme Therapeutics, Inc. is an American company headquartered in San Diego, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Halozyme Therapeutics, Inc. headquartered?
Halozyme Therapeutics, Inc. is headquartered in San Diego, California, United States.
Is Halozyme Therapeutics, Inc. publicly traded?
Yes — Halozyme Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol HALO on the NASDAQ.
What does Halozyme Therapeutics, Inc. do?
Halozyme Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
